Clinical Benefit of Statins in Korean Patients with Acute Myocardial Infarction: Experience of the Korea Acute Myocardial Infarction Registry
4
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor) are among the most important medications for treating patients with acute myocardial infarction (AMI). Herein, we review the clinical benefit and future scope of statin therapy in Korean patients with AMI from the experience of the Korea AMI Registry. Statins are effective and safe in AMI patients, even in those with very low low-density lipoprotein cholesterol (LDL-C). Peri-procedural statin treatment could reduce the incidence of early stent thrombosis in patients with AMI after percutaneous coronary intervention. Reduction of high sensitivity C-reactive protein levels in patients with AMI plays an important role in the beneficial effect of statins on regression and compositional change of coronary plaques. Obtaining ≥50% reduction in LDL-C is associated with better clinical outcomes after AMI, whereas achieving <70 mg/dL LDL-C is not. Statin therapy has positive effects on clinical outcomes in patients with cardiogenic shock, ischemic heart failure, chronic kidney disease, and vasospasm. The combination of high-dose statin plus N-acetyl cysteine is associated with lower incidence of contrast-induced nephropathy in patients who underwent primary percutaneous coronary intervention. Moderate-intensity pitavastatin therapy is associated with a lower incidence of new-onset diabetes mellitus in patients with AMI and has similar clinical outcomes to moderate-intensity atorvastatin and rosuvastatin therapy. Future studies are required to assess the optimal intensity and LDL-C target concerning statin therapy, and the implementation of guidelines based cholesterol lowering practice in Korean patients with AMI.
Abstract
Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor) are among the most important medications for treating patients with acute myocardial infarction (AMI). Herein, we review the clinical benefit and future scope of statin therapy in Korean patients with AMI from the experience of the Korea AMI Registry. Statins are effective and safe in AMI patients, even in those with very low low-density lipoprotein cholesterol (LDL-C). Peri-procedural statin treatment could reduce the incidence of early stent thrombosis in patients with AMI after percutaneous coronary intervention. Reduction of high sensitivity C-reactive protein levels in patients with AMI plays an important role in the beneficial effect of statins on regression and compositional change of coronary plaques. Obtaining ≥50% reduction in LDL-C is associated with better clinical outcomes after AMI, whereas achieving <70 mg/dL LDL-C is not. Statin therapy has positive effects on clinical outcomes in patients with cardiogenic shock, ischemic heart failure, chronic kidney disease, and vasospasm. The combination of high-dose statin plus N-acetyl cysteine is associated with lower incidence of contrast-induced nephropathy in patients who underwent primary percutaneous coronary intervention. Moderate-intensity pitavastatin therapy is associated with a lower incidence of new-onset diabetes mellitus in patients with AMI and has similar clinical outcomes to moderate-intensity atorvastatin and rosuvastatin therapy. Future studies are required to assess the optimal intensity and LDL-C target concerning statin therapy, and the implementation of guidelines based cholesterol lowering practice in Korean patients with AMI.
참고문헌 (43)
- 이기홍, "New Horizons of Acute Myocardial Infarction: From the Korea Acute Myocardial Infarction Registry", Journal of Korean Medical Science, 28(2), pp.173~180 (2013), 대한의학회
- 김현국, "The scientific achievements of the decades in Korean Acute Myocardial Infarction Registry", The Korean Journal of Internal Medicine, 29(6), pp.703~712 (2014), 대한내과학회[DOI]
- 심두선, "Differences in the Korea Acute Myocardial Infarction Registry Compared with Western Registries", Korean Circulation Journal, 47(6), pp.811~822 (2017), 대한심장학회[DOI]
- 김용철, "Current status of acute myocardial infarction in Korea", The Korean Journal of Internal Medicine, 34(1), pp.1~10 (2019), 대한내과학회[DOI]
- score), "Am J Cardiol", 2011, 965~971
- Lee SH, "Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention", Eur Heart J Cardiovasc Pharmacother (2020)
- Lee KH, "Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol", J Am Coll Cardiol, 58, pp.1664~1671 (2011)
- Piao ZH, "Benefits of statin therapy in patients with acute myocardial infarction with serum low-density lipoprotein cholesterol ≤ 50 mg", dl, 2017, pp.120, 174~180
- Hwang D, "Effects of statin intensity on clinical outcome in acute myocardial infarction patients", Circ J, 82, pp.1112~1120 (2018)
- 심두선, "Intensity of Statin Treatment in Korean Patients with Acute Myocardial Infarction and Very Low LDL Cholesterol", 지질·동맥경화학회지, 8(2), pp.208~220 (2019), 한국지질동맥경화학회[DOI]
- Jeong HC, "Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high-sensitivity C-reactive protein", Int J Cardiol, 167, pp.1848~1853 (2013)
- Park JS, "Lower in-hospital ventricular tachyarrhythmia in patients with acute myocardial infarction receiving prior statin therapy", Angiology, 69, pp.892~899 (2018)
- Hong YJ, "Effect of pitavastatin treatment on changes of plaque volume and composition according to the reduction of high-sensitivity C-reactive protein levels", J Cardiol, 60, pp.277~282 (2012)
- 김민철, "Comparison of Clinical Outcomes of Hydrophilic and Lipophilic Statins in Patients with Acute Myocardial Infarction", The Korean Journal of Internal Medicine, 26(3), pp.294~303 (2011), 대한내과학회
- Kim MC, "Early statin therapy within 48 hours decreased one-year major adverse cardiac events in patients with acute myocardial infarction", Int Heart J, 52, pp.1~6 (2011)
- Cho KH, "Comparison of the effects of two low-density lipoprotein cholesterol goals for secondary prevention after acute myocardial infarction in real-world practice : ≥ 50% reduction from baseline versus <70 mg", dL, 2015, pp.187, 478~485
- Kang DO, "Time-dependent prognostic effect of high sensitivity C-reactive protein with statin therapy in acute myocardial infarction", J Cardiol, 74, pp.74~83 (2019)
- Kim YH, "Different statin effects of ST-elevation versus non-ST-elevation acute myocardial infarction after stent implantation", Am J Med Sci, 359, pp.156~167 (2020)
- 심두선, "Effect of Early Statin Treatment in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction", Korean Circulation Journal, 43(2), pp.100~109 (2013), 대한심장학회
- Cho J, "Statin has more protective effects in AMI patients with higher plasma BNP or NT-proBNP level, but not with lower left ventricular ejection fraction", J Cardiol, 71, pp.375~381 (2018)
- Jeong HC, "Effect of statin treatment in patients with acute myocardial infarction and left ventricular systolic dysfunction according to the level of high-sensitivity C-reactive protein", Int Heart J, 55, pp.106~112 (2014)
- Lim SY, "Effect on short-and long-term major adverse cardiac events of statin treatment in patients with acute myocardial infarction and renal dysfunction", Am J Cardiol, 109, pp.1425~1430 (2012)
- Piao ZH, "Benefit of statin therapy in patients with coronary spasm-induced acute myocardial infarction", J Cardiol, 68, pp.7~12 (2016)
- Choo EH, "Prognosis and predictors of mortality in patients suffering myocardial infarction with non-obstructive coronary arteries", J Am Heart Assoc, 8, pp.e011990~ (2019)
- Park SH, "Effects of combination therapy of statin and N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention", Int J Cardiol, 212, pp.100~106 (2016)
- Choi JY, "Effect of pitavastatin compared with atorvastatin and rosuvastatin on new-onset diabetes mellitus in patients with acute myocardial infarction", Am J Cardiol, 122, pp.922~928 (2018)
- Ji MS, "Clinical outcome of statin plus ezetimibe versus high-intensity statin therapy in patients with acute myocardial infarction propensity-score matching analysis", Int J Cardiol, 225, pp.50~59 (2016)
- Ferrari R, "Not just numbers, but years of science : putting the ACE inhibitor-ARB meta-analyses into context", Int J Cardiol, 166, pp.286~288 (2013)
- Kim YH, "A comparison between statin with ACE inhibitor or ARB therapy in STEMI patients who underwent successful PCI with drug-eluting stents", Atherosclerosis, 289, pp.109~117 (2019)
- Kim MC, "Impact of postdischarge statin withdrawal on long-term outcomes in patients with acute myocardial infarction", Am J Cardiol, 115, pp.1~7 (2015)
- 이상학, "Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea", 지질·동맥경화학회지, 8(2), pp.242~251 (2019), 한국지질동맥경화학회[DOI]
- Cannon CP, "Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins : the ODYSSEY COMBO II randomized controlled trial", Eur Heart J, 36, pp.1186~1194 (2015)
- Schwartz GG, "Alirocumab and cardiovascular outcomes after acute coronary syndrome", N Engl J Med, 379, pp.2097~2107 (2018)
- Ray KK, "Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes : a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial", Lancet Diabetes Endocrinol, 7, pp.618~628 (2019)
- Koh KK, "A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan(ODYSSEY KT)", J Clin Lipidol, 12, pp.162~172 (2018)
- Birmingham BK, "Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States", Eur J Clin Pharmacol, 71, pp.329~340 (2015)
- Li YF, "The difference between Asian and Western in the effect of LDL-C lowering therapy on coronary atherosclerotic plaque : a meta-analysis report", BMC Cardiovasc Disord, 15, pp.6~ (2015)
- Fulcher J, "Efficacy and safety of LDL-lowering therapy among men and women : meta-analysis of individual data from 174, 000 participants in 27 randomised trials", Lancet, 385, pp.1397~1405 (2015)
- Mihaylova B, "The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease : meta-analysis of individual data from 27 randomised trials", Lancet, 380, pp.581~590 (2012)
- Silverman MG, "Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions : a systematic review and meta-analysis", JAMA, 316, pp.1289~1297 (2016)
- Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
- Mach F, "2019 ESC", EAS Guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk, 2020, pp.41, 111~188
- 이은정, "2018 Guidelines for the management of dyslipidemia", The Korean Journal of Internal Medicine, 34(4), pp.723~771 (2019), 대한내과학회[DOI]